C. Morel

Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: A cost-utility model focusing on gram-negative bacteria.

Jann-Tay Wang, Sung-Ching Pan, Guan-Jhou Chen, 2019, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD

Meilan K. Han, R. Ray, B. Hahn, 2018, npj Primary Care Respiratory Medicine.

Comparative Efficacy of Second- and Subsequent-line Treatments for Metastatic NSCLC: A Fractional Polynomials Network Meta-analysis of Cancer Immunotherapies.

C. Watkins, D. Gandara, R. Rosenthal, 2019, Clinical lung cancer.

Cost per response for abatacept versus adalimumab in patients with seropositive, erosive early rheumatoid arthritis in the US, Germany, Spain, and Canada

C. Baerwald, M. Bergman, R. Postema, 2019, Rheumatology International.